Acurx files S-1 to register 1.5 million more shares for Lincoln Park sale facility

Acurx Pharmaceuticals, Inc. filed a Form S-1 with the Securities and Exchange Commission on September 8, 2026, covering the potential resale of up to 1,500,000 shares of its common stock by Lincoln Park Capital Fund, LLC. The prospectus relates to the resale of up to 1,500,000 shares of common stock by Lincoln Park pursuant to a purchase agreement dated May 8, 2025.¹

Under that May 8, 2025 agreement, Lincoln Park committed to purchase up to $12.0 million of Acurx common stock, of which $9.2 million had already been issued and sold as of the date of this prospectus, and Acurx issued 44,963 commitment shares to Lincoln Park as a fee for the arrangement.¹ Aside from the commitment shares, Acurx may sell shares to Lincoln Park at its discretion over a 24-month period from the commencement date through May 29, 2027.¹

The company said it may receive up to $2.8 million in additional gross proceeds under the purchase agreement, on top of the $9.2 million already received, once other conditions in the agreement are satisfied.¹ Across four prior registration statements, Acurx has registered an aggregate of 3,179,963 shares of common stock, of which 3,135,000 have been sold to Lincoln Park to date.¹

Acurx common stock trades on Nasdaq under the symbol "ACXP," and the last reported sale price on September 4, 2026 was $1.42 per share.¹ The company had 5,559,405 shares outstanding prior to the offering, which would rise to 7,059,405 shares if the full 1,500,000 shares are sold.¹ Any proceeds from sales to Lincoln Park are intended for working capital and general corporate purposes.¹